Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28587062
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28587062
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Genes+(Basel)
2017 ; 8
(6
): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
MYC Deregulation in Primary Human Cancers
#MMPMID28587062
Kalkat M
; De Melo J
; Hickman KA
; Lourenco C
; Redel C
; Resetca D
; Tamachi A
; Tu WB
; Penn LZ
Genes (Basel)
2017[May]; 8
(6
): ä PMID28587062
show ga
MYC regulates a complex biological program by transcriptionally activating and
repressing its numerous target genes. As such, MYC is a master regulator of many
processes, including cell cycle entry, ribosome biogenesis, and metabolism. In
cancer, the activity of the MYC transcriptional network is frequently
deregulated, contributing to the initiation and maintenance of disease.
Deregulation often leads to constitutive overexpression of MYC, which can be
achieved through gross genetic abnormalities, including copy number alterations,
chromosomal translocations, increased enhancer activity, or through aberrant
signal transduction leading to increased MYC transcription or increased MYC mRNA
and protein stability. Herein, we summarize the frequency and modes of MYC
deregulation and describe both well-established and more recent findings in a
variety of cancer types. Notably, these studies have highlighted that with an
increased appreciation for the basic mechanisms deregulating MYC in cancer, new
therapeutic vulnerabilities can be discovered and potentially exploited for the
inhibition of this potent oncogene in cancer.